133 related articles for article (PubMed ID: 16699172)
1. Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
Bonn S; Herrero S; Breitenlechner CB; Erlbruch A; Lehmann W; Engh RA; Gassel M; Bossemeyer D
J Biol Chem; 2006 Aug; 281(34):24818-30. PubMed ID: 16699172
[TBL] [Abstract][Full Text] [Related]
2. Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT).
Gassel M; Breitenlechner CB; Rüger P; Jucknischke U; Schneider T; Huber R; Bossemeyer D; Engh RA
J Mol Biol; 2003 Jun; 329(5):1021-34. PubMed ID: 12798691
[TBL] [Abstract][Full Text] [Related]
3. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
Davies TG; Verdonk ML; Graham B; Saalau-Bethell S; Hamlett CC; McHardy T; Collins I; Garrett MD; Workman P; Woodhead SJ; Jhoti H; Barford D
J Mol Biol; 2007 Mar; 367(3):882-94. PubMed ID: 17275837
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into AGC kinase inhibition.
Breitenlechner C; Gassel M; Engh R; Bossemeyer D
Oncol Res; 2004; 14(6):267-78. PubMed ID: 15206489
[TBL] [Abstract][Full Text] [Related]
5. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
6. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
Jacobs M; Hayakawa K; Swenson L; Bellon S; Fleming M; Taslimi P; Doran J
J Biol Chem; 2006 Jan; 281(1):260-8. PubMed ID: 16249185
[TBL] [Abstract][Full Text] [Related]
7. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Burthem J; Rees-Unwin K; Mottram R; Adams J; Lucas GS; Spooncer E; Whetton AD
Leukemia; 2007 Aug; 21(8):1708-14. PubMed ID: 17554385
[TBL] [Abstract][Full Text] [Related]
8. Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.
Pflug A; de Oliveira TM; Bossemeyer D; Engh RA
Biochem J; 2011 Nov; 440(1):85-93. PubMed ID: 21774789
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity.
Breitenlechner C; Gassel M; Hidaka H; Kinzel V; Huber R; Engh RA; Bossemeyer D
Structure; 2003 Dec; 11(12):1595-607. PubMed ID: 14656443
[TBL] [Abstract][Full Text] [Related]
10. Amino acid derived quinazolines as Rock/PKA inhibitors.
Chowdhury S; Chen YT; Fang X; Grant W; Pocas J; Cameron MD; Ruiz C; Lin L; Park H; Schröter T; Bannister TD; Lograsso PV; Feng Y
Bioorg Med Chem Lett; 2013 Mar; 23(6):1592-9. PubMed ID: 23416002
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of Rho-associated kinase (Rho-kinase/ROCK/ROK) substrates by protein kinases A and C.
Kang JH; Jiang Y; Toita R; Oishi J; Kawamura K; Han A; Mori T; Niidome T; Ishida M; Tatematsu K; Tanizawa K; Katayama Y
Biochimie; 2007 Jan; 89(1):39-47. PubMed ID: 16996192
[TBL] [Abstract][Full Text] [Related]
12. Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool.
Åberg E; Lund B; Pflug A; Gani OA; Rothweiler U; de Oliveira TM; Engh RA
Biol Chem; 2012 Oct; 393(10):1121-9. PubMed ID: 23092797
[TBL] [Abstract][Full Text] [Related]
13. Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design.
Oruganty K; Kannan N
Biochim Biophys Acta; 2013 Jul; 1834(7):1322-9. PubMed ID: 23499783
[TBL] [Abstract][Full Text] [Related]
14. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
15. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
Vankayalapati H; Bearss DJ; Saldanha JW; Muñoz RM; Rojanala S; Von Hoff DD; Mahadevan D
Mol Cancer Ther; 2003 Mar; 2(3):283-94. PubMed ID: 12657723
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
17. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity.
Engh RA; Girod A; Kinzel V; Huber R; Bossemeyer D
J Biol Chem; 1996 Oct; 271(42):26157-64. PubMed ID: 8824261
[TBL] [Abstract][Full Text] [Related]
19. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
[TBL] [Abstract][Full Text] [Related]
20. A molecular mechanism of P-loop pliability of Rho-kinase investigated by molecular dynamic simulation.
Gohda K; Hakoshima T
J Comput Aided Mol Des; 2008 Nov; 22(11):789-97. PubMed ID: 18415022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
